Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials

Biologicals

Volumn 38, Issue 1, 2010, Pages 144-149

  Su, Yunpeng ^a,b   Li, Shi Yan ^a   Ghosh, Sunil ^a   Ortiz, Janelle ^a   Hogge, Donna E ^c   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Diphtheria toxin; Interleukin 3

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTILEUKEMIC AGENT; DIPHTHERIA TOXIN INTERLEUKIN 3 FUSION PROTEIN; ENDOTOXIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSTRUMENT STERILIZATION; MASS SPECTROMETRY; MOLECULAR WEIGHT; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR BINDING; TEMPERATURE;

AMINO ACID SUBSTITUTION; BONE MARROW CELLS; CELLS, CULTURED; CLINICAL TRIALS, PHASE I AS TOPIC; DIPHTHERIA TOXIN; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; GENETIC VARIATION; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, ACUTE; LYSINE; RECOMBINANT FUSION PROTEINS; STERILIZATION; TOXICITY TESTS; TRYPTOPHAN;

EID: 77649179677     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.08.016     Document Type: Article

References (21)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics, 2003. CA Cancer J Clin 53 1 (2003) 5-26
2. Bennett J.M., Young M.L., Andersen J.W., Cassileth P.A., Tallman M.S., Paietta E., et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 80 11 Suppl (1997) 2205-2209
3. Clark J., and Smith R. BMJ Publishing Group to launch an international campaign to promote academic medicine. BMJ 327 7422 (2003) 1001-1002
4. Larson R.A. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. Leukemia 17 3 (2003) 488-491
5. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14 10 (2000) 1777-1784
6. Alexander R.L., Ramage J., Kucera G.L., Caligiuri M.A., and Frankel A.E. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 25 10 (2001) 875-881
7. Draper R.K., and Simon M.I. The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement. J Cell Biol 87 3 Pt 1 (1980) 849-854
8. Honjo T., Nishizuka Y., Kato I., and Hayaishi O. Adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin. J Biol Chem 246 13 (1971) 4251-4260
9. Yamaizumi M., Mekada E., Uchida T., and Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15 1 (1978) 245-250
10. Feuring-Buske M., Frankel A.E., Alexander R.L., Gerhard B., and Hogge D.E. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62 6 (2002) 1730-1736
11. Frankel A.E., McCubrey J.A., Miller M.S., Delatte S., Ramage J., Kiser M., et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 14 4 (2000) 576-585
12. Lopez A.F., Shannon M.F., Barry S., Phillips J.A., Cambareri B., Dottore M., et al. A human interleukin 3 analog with increased biological and binding activities. Proc Natl Acad Sci U S A 89 24 (1992) 11842-11846
13. Klein B.K., Shieh J.J., Grabbe E., Li X., Welply J.K., and McKearn J.P. Receptor binding kinetics of human IL-3 variants with altered proliferative activity. Biochem Biophys Res Commun 288 5 (2001) 1244-1249
14. Liu T.F., Urieto J.O., Moore J.E., Miller M.S., Lowe A.C., Thorburn A., et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 32 3 (2004) 277-281
15. Frankel A.E., Ramage J., Kiser M., Alexander R., Kucera G., and Miller M.S. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 13 (2000) 575-581
16. Frankel A.E., Hall P.D., Burbage C., Vesely J., Willingham M., Bhalla K., et al. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood 90 (1997) 3654-3661
17. Su Y., Vanderlaag K., Ireland C., Ortiz J., Grage H., Safe S., et al. 1,1-Bis(3′-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. Breast Cancer Res 9 4 (2007) R56
18. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250 (1975) 4007-4021
19. Su Y., Ortiz J., Liu S., Bugge T.H., Singh R., Leppla S.H., et al. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Res 67 7 (2007) 3329-3336
20. Hogge D.E., Yalcintepe L., Wong S.H., Gerhard B., and Frankel A.E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12 4 (2006 Feb 15) 1284-1291
21. Pastrana D.V., and FitzGerald D.J. A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin. Anal Biochem 353 2 (2006 Jun 15) 266-271